Back to Search Start Over

Clinical features, prognostic stratification, and treatment of advanced-stage non-nasal type extranodal natural killer/T-cell lymphoma: a multi-institutional real-world study.

Authors :
Wei, Yu-Ce
Liu, Wei-Xin
Qi, Fei
Zhang, Chang-Gong
Zheng, Bao-Min
Xie, Yan
Chen, Bo
Zhang, Di
Liu, Wei-Ping
Fang, Hui
Chai, Yue
Qi, Shu-Nan
Li, Ye-Xiong
Wang, Wei-Hu
Song, Yu-Qin
Zhu, Jun
Dong, Mei
Source :
Annals of Hematology. Jan2024, Vol. 103 Issue 1, p163-174. 12p.
Publication Year :
2024

Abstract

The present study aimed to investigate the clinical features, prognosis, and treatment of advanced-stage non-nasal type extranodal natural killer/T-cell lymphoma (ENKTCL). This real-world study retrospectively reviewed 56 newly diagnosed advanced-stage non-nasal type ENKTCL patients from two large-scale Chinese cancer centers in the last 10–15 years and screened 139 newly diagnosed advanced-stage nasal type ENKTCLs admitted during the same period for comparison. The non-nasal type ENKTCLs exhibited significantly higher Ki-67 expression levels compared to nasal type disease (P = 0.011). With a median follow-up duration of 75.03 months, the non-nasal group showed slightly inferior survival outcomes without statistically significant differences compared to the nasal group (median overall survival (OS): 14.57 vs. 21.53 months, 5-year OS: 28.0% vs. 38.5%, P = 0.120). Eastern Cooperative Oncology Group (ECOG) score ≥ 2 (hazard ratio (HR) = 2.18, P = 0.039) and lactic dehydrogenase (LDH) elevation (HR = 2.44, P = 0.012) were significantly correlated with worse OS in the non-nasal group. First-line gemcitabine-based chemotherapy regimens showed a trend toward slightly improved efficacy and survival outcomes compared to non-gemcitabine-based ones in the present cohort of non-nasal ENKTCLs (objective response rate: 91.7% vs. 63.6%, P = 0.144; complete response rate: 50.0% vs. 33.3%, P = 0.502; median progression-free survival: 10.43 vs. 3.40 months, P = 0.106; median OS: 25.13 vs. 9.30 months, P = 0.125), which requires further validation in larger sample size studies. Advanced-stage non-nasal type patients could achieve comparable prognosis with nasal cases after rational therapy. The modified nomogram-revised index (including age, ECOG score, and LDH) and modified international prognostic index (including age, ECOG score, LDH, and number of extranodal involvement) functioned effectively for prognostic stratification in non-nasal type ENKTCLs. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
09395555
Volume :
103
Issue :
1
Database :
Academic Search Index
Journal :
Annals of Hematology
Publication Type :
Academic Journal
Accession number :
174558765
Full Text :
https://doi.org/10.1007/s00277-023-05455-4